type 1 and type 2 diabetes
Endocrinology · 2007–2018
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| insulin aspart Treatment of type 1 and type 2 diabetes mellitus requiring bolus insulin, delivered as bolus subcutaneous injections or via external continuous subcutaneous… | Nov 2018 | Recommended with restriction | input received JDRF Australia |
| insulin degludec with insulin aspart Treatment of adult patients with type 1 and type 2 diabetes mellitus where insulin treatment is necessary to improve glycaemic control. | Nov 2017 | Not recommended | input received Australian Diabetes Society |
| insulin lispro Treatment of type 1 and type 2 diabetes mellitus in patients who require higher daily insulin doses of >20 U. | Nov 2017 | Recommended | none received |
| insulin glargine Treatment of adults with diabetes mellitus (type 1 and type 2 diabetes). | Jul 2015 | Recommended | 2 individuals |
| insulin degludec Treatment of patients with type 1 or type 2 diabetes mellitus requiring insulin therapy. | Mar 2013 | Recommended | no section in document |
| insulin glulisine Treatment of Type 1 and Type 2 diabetes mellitus in adults and children older than 12 years who require insulin for the control of hyperglycaemia. | Mar 2007 | Recommended | no section in document |
Who spoke
JDRF Australia · Australian Diabetes Society
What the PBS pays
$439M in government benefit over 2024–25, across 1,960,892 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| insulin aspart | $142.1M |
| insulin degludec with insulin aspart | $142.1M |
| insulin glargine | $73.4M |
| insulin degludec | $72.8M |
| insulin lispro | $7.3M |
| insulin glulisine | $1.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.